Table 1.
Baseline Patient Characteristics
| Group 1 (n=31) | Group 2 (n=52) | P Value | |
|---|---|---|---|
| Sex, male | 25 (80.6) | 37 (71.2) | 0.336 |
| Age, y | 68.25±8.43 | 67.60±10.85 | 0.761 |
| Diabetes mellitus | 8 (25.8) | 20 (38.5) | 0.238 |
| Hypertension | 20 (64.5) | 38 (73.1) | 0.411 |
| Single‐chamber ICD | 27 (87.1) | 0 (0) | <0.001 |
| Dual‐chamber ICD | 4 (12.9) | 13 (25.0) | 0.187 |
| CRTD | 0 | 39 (75.0) | <0.001 |
| Primary prevention | 15 (48.4) | 42 (80.8) | <0.001 |
| Secondary prevention | 16 (51.6) | 10 (19.2) | <0.001 |
| VT/VF | 16 (51.6) | 10 (19.2) | <0.001 |
| DCM | 14 (45.2) | 28 (53.8) | 0.444 |
| HCM | 3 (9.7) | 6 (11.5) | 0.792 |
| ICM | 2 (6.1) | 13 (25.0) | 0.026 |
| Average heart rate, beats/min | 84.23±12.01 | 88.90±16.85 | 0.095 |
| QRS duration | 95.81±24.03 | 96.40±17.05 | 0.193 |
| LVEF | 42.77±15.97 | 35.09±11.65 | <0.001 |
| LVEF ≤35% | 17 (54.8) | 42 (80.8) | 0.012 |
| NYHA class | |||
| II | 17 (54.8) | 18 (34.6) | 0.071 |
| III | 11 (35.5) | 29 (55.8) | 0.074 |
| IV | 3 (9.7) | 5 (9.6) | 0.993 |
Data are shown as mean±SD or n (%). CRTD indicates cardiac resynchronization therapy defibrillator; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter‐defibrillator; ICM, ischemic cardiomyopathy; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; VF, ventricular fibrillation; VT, ventricular tachycardia.